Canine lyme disease vaccine
The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.
1. An immunogenic composition comprising two or more alphavirus RNA replicon particles each individually encoding one or more Borrelia burgdorferi antigens;
wherein one alphavirus RNA replicon particle encodes a Borrelia burgdorferi outer surface protein A (OspA), wherein the OspA consists of the amino acid sequence of SEQ ID NO: 2,
and wherein another alphavirus RNA replicon particle encodes a Borrelia burgdorferi outer surface protein C (OspC), wherein the OspC consists of the amino acid sequence of SEQ ID NO: 4; wherein both OspA-borreliacidal and OspC-borreliacidal antibodies are induced in a canine when said canine is immunized with said immunogenic composition.
2. A vaccine to aid in the prevention of disease due to Borrelia burgdorferi infection comprising the immunogenic composition of claim 1 , and a pharmaceutically acceptable carrier.
3. An immunogenic composition comprising an alphavirus RNA replicon particle that encodes two or more Borrelia burgdorferi antigens; wherein at least one Borrelia burgdorferi antigen is an outer surface protein A (OspA) and wherein at least one other Borrelia burgdorferi antigen is an outer surface protein C (OspC), wherein at least one OspA comprises the amino acid sequence of SEQ ID NO: 2, and at least one OspC, comprises the amino acid sequence of SEQ ID NO: 4; and wherein both OspA-borreliacidal and OspC-borreliacidal antibodies are induced in a canine when said canine is immunized with said immunogenic composition.
4. The immunogenic composition of claim 3 comprising a first and a second alphavirus RNA replicon particle each individually encoding an OspA and an OspC wherein the first RNA replicon particle comprises a nucleic acid sequence encoding OspA that is located upstream of a nucleic acid sequence encoding OspC, and the second RNA replicon particle comprises a nucleic acid sequence encoding OspC that is located upstream of a nucleic acid sequence encoding OspA.
5. The immunogenic composition of claim 3 , wherein at least one of the alphavirus RNA replicon particles is a Venezuelan Equine Encephalitis Virus (VEEV) RNA replicon particle.
6. The immunogenic composition of claim 5 , that comprises one or more additional alphavirus RNA replicon particles which encode a Borrelia burgdorferi antigen selected from the group consisting of a second OspA that originates from a different strain of Borrelia burgdorferi than the OspA, a second OspC that originates from a different strain of Borrelia burgdorferi than the OspC, and any combination thereof.
7. The immunogenic composition of claim 6 , wherein the one or more additional alphavirus RNA replicon particles are VEEV RNA replicon particles.
8. The immunogenic composition of claim 5 , wherein at least one OspA consists of the amino acid sequence of SEQ ID NO: 2 and at least one OspC consists of the amino acid sequence of SEQ ID NO: 4.
9. A vaccine to aid in the prevention of disease due to Borrelia burgdorferi infection comprising the immunogenic composition of claim 5 and a pharmaceutically acceptable carrier.
10. The vaccine composition of claim 9 , further comprising at least one non- Borrelia immunogen for eliciting protective immunity to a non- Borrelia pathogen.
11. The vaccine of claim 10 , wherein the non- Borrelia immunogen is a killed or attenuated non- Borrelia pathogen selected from the group of killed or attenuated non- Borrelia pathogens consisting of canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, canine coronavirus, canine influenza virus, Leptospira serovars, Leishmania organisms, Bordetella bronchiseptica, Mycoplasma species, rabies virus, Ehrlichia canis , an Anaplasma species, and any combination thereof.
12. The vaccine of claim 11 , wherein the Mycoplasma species comprises Mycoplasma cynos.
13. The vaccine of claim 12 , wherein the Leptospira serovars are selected from the group consisting of Leptospira kirschneri serovar grippotyphosa, Leptospira interrogans serovar canicola, Leptospira interrogans serovar icterohaemorrhagiae, Leptospira interrogans serovar pomona , and any combination thereof.
14. The vaccine composition of claim 9 , further comprising an alphavirus RNA replicon particle comprising a nucleotide sequence encoding at least one protein antigen or an antigenic fragment thereof from a non- Borrelia immunogen.
15. The vaccine of claim 14 , wherein the non- Borrelia immunogen comes from a non- Borrelia pathogen selected from the group consisting of canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, canine coronavirus, canine influenza virus, Leptospira serovars, Leishmania organisms, Bordetella bronchiseptica, Mycoplasma species, rabies virus, Ehrlichia canis , an Anaplasma species, and any combination thereof.
16. The vaccine composition of claim 9 , that is a nonadjuvanted vaccine.
17. A method of immunizing a mammal against a pathogenic Borrelia genospecies comprising administering to the mammal an immunologically effective amount of the vaccine of claim 9 , 10 , 14 , 15 , 11 , 12 , 13 or 16 .